UnitedHealth rebuffs Cologuard

UnitedHealth Group Inc. (NYSE:UNH) on Monday instituted a medical policy that concludes the evidence is insufficient to support the diagnostic accuracy of fecal DNA tests to screen for colorectal cancer in asymptomatic, average-risk patients.

The policy applies to the only approved product, the Cologuard non-invasive DNA screening test from Exact Sciences Corp. (NASDAQ:EXAS). ...